Eptifibatide and ST Segment Resolution Following Primary PCI
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open label, randomized trial of 100 patients who present to the
cardiac catheterization laboratory with an ST Elevation Myocardial Infarction for primary
PCI. Patients may receive up-front unfractionated heparin or low molecular weight heparin,
but not glycoprotein IIb/IIIa inhibitors or thrombolytics. Patients will be consented prior
to the diagnostic catheterization and will be randomized once the patient is deemed amenable
to PCI to receive eptifibatide or no eptifibatide just prior to or at the time of primary
angioplasty. Patients will be randomized in a 1:1 fashion. All patients will be assessed for
the primary endpoint of ST resolution at 60 minutes post PCI and followed throughout the
duration of the hospitalization and up to 30 days for secondary endpoint evaluation.